These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 27520369)

  • 1. Conformational modulation mediated by polyglutamine expansion in CAG repeat expansion disease-associated proteins.
    Verani M; Bustamante M; Martufi P; Daldin M; Cariulo C; Azzollini L; Fodale V; Puglisi F; Weiss A; Macdonald D; Petricca L; Caricasole A
    Biochem Biophys Res Commun; 2016 Sep; 478(2):949-55. PubMed ID: 27520369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy.
    Fodale V; Kegulian NC; Verani M; Cariulo C; Azzollini L; Petricca L; Daldin M; Boggio R; Padova A; Kuhn R; Pacifici R; Macdonald D; Schoenfeld RC; Park H; Isas JM; Langen R; Weiss A; Caricasole A
    PLoS One; 2014; 9(12):e112262. PubMed ID: 25464275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models.
    Daldin M; Fodale V; Cariulo C; Azzollini L; Verani M; Martufi P; Spiezia MC; Deguire SM; Cherubini M; Macdonald D; Weiss A; Bresciani A; Vonsattel JG; Petricca L; Marsh JL; Gines S; Santimone I; Marano M; Lashuel HA; Squitieri F; Caricasole A
    Sci Rep; 2017 Jul; 7(1):5070. PubMed ID: 28698602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin.
    Caron NS; Desmond CR; Xia J; Truant R
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14610-5. PubMed ID: 23898200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional alterations in the androgen receptor in spinal bulbar muscular atrophy.
    McEwan IJ
    Biochem Soc Trans; 2001 May; 29(Pt 2):222-7. PubMed ID: 11356158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
    Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
    Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
    Stoyas CA; La Spada AR
    Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF; Jiang H; Tang JG; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Kennedy's disease: expansion of the CAG trinucleotide].
    Domitrz I; Jedrzejowska M; Lipowska M; Siddique T; Kwieciński H
    Neurol Neurochir Pol; 2001; 35(1 Suppl):107-14. PubMed ID: 11732276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAG-encoded polyglutamine length polymorphism in the human genome.
    Butland SL; Devon RS; Huang Y; Mead CL; Meynert AM; Neal SJ; Lee SS; Wilkinson A; Yang GS; Yuen MM; Hayden MR; Holt RA; Leavitt BR; Ouellette BF
    BMC Genomics; 2007 May; 8():126. PubMed ID: 17519034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
    Reis SD; Pinho BR; Oliveira JMA
    Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Expansion of CAG, CAA, and Mixed CAG/CAA Repeats.
    Figura G; Koscianska E; Krzyzosiak WJ
    Int J Mol Sci; 2015 Aug; 16(8):18741-51. PubMed ID: 26270660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trinucleotide repeat expansion in neurological disease.
    La Spada AR; Paulson HL; Fischbeck KH
    Ann Neurol; 1994 Dec; 36(6):814-22. PubMed ID: 7998766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.
    Pollitt SK; Pallos J; Shao J; Desai UA; Ma AA; Thompson LM; Marsh JL; Diamond MI
    Neuron; 2003 Nov; 40(4):685-94. PubMed ID: 14622574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinocerebellar ataxia 7 (SCA7).
    Lebre AS; Brice A
    Cytogenet Genome Res; 2003; 100(1-4):154-63. PubMed ID: 14526176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenic agent in Drosophila models of 'polyglutamine' diseases.
    McLeod CJ; O'Keefe LV; Richards RI
    Hum Mol Genet; 2005 Apr; 14(8):1041-8. PubMed ID: 15757976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SCA17, a novel polyglutamine disease caused by the expansion of polyglutamine tracts in TATA-binding protein].
    Nakamura K
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1123-5. PubMed ID: 12235815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.
    Mackenzie IR; Butland SL; Devon RS; Dwosh E; Feldman H; Lindholm C; Neal SJ; Ouellette BF; Leavitt BR
    BMC Neurol; 2006 Aug; 6():32. PubMed ID: 16945149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.